[Pe-058] 一般演題ポスターセッション（英語）058

[Pe-058-4] Randomized controlled study of the efficacy of natalizumab 6-week vs continued 4-week dosing for MS

^○Foley John¹, Gilles Defer², Lana Zhovtis Ryerson³, Jeffrey A. Cohen⁴, Doug L. Arnold⁵, Helmut Butzkueven⁶, Gary Cutter⁷, Gavin Giovannoni⁸, Joep Killestein⁹, Heinz Wiendl¹⁰, Karen Smirnakis¹¹, Shan Xiao¹¹, George Kong¹¹, Robert Kuhelj¹¹, Nolan Campbell¹¹ (1.Rocky Mountain MS Clinic, 2.Institute of Translational Neurology, University of Munster, 3.Biogen, 4.Centre Hospitalier Universitaire de Caen, 5.NYU Langone Health, New York University, 6.Cleveland Clinic, 7.Montreal Neurological Institute, McGill University, and NeuroRx Research, 8.Central Clinical School, Monash University, 9.University of Alabama School of Public Health, 10.Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 11.MS Centre Amsterdam, VU University Medical Centres)